CAMEO+ eventHEALTH2026-04-18馃嚭馃嚫
Trump signs order to speed psychedelics review, including ibogaine
source: President Donald Trump / U.S. federal government
On 2026-04-18, President Donald Trump signed an executive order to ease restrictions on ibogaine and speed U.S. research into psychedelic drugs. The order also opened a pathway for use under the FDA's Right To Try rule and included a $50 million federal research investment. The announcement was made in Washington, D.C., with HHS Secretary Robert F. Kennedy Jr. present.
0.24Significance4.0Magnitude0.4Systemic0.3Market3Articles
Location
Washington, D.C.District of ColumbiaNorth AmericaUnited StatesNorth America38.907, -77.037
Story Links
cameoplus_political 路 2026-04-18 路 5 articles
Trump signs order easing restrictions on psychedelic drugs
cameoplus_health 路 2026-04-18 路 4 articles
Trump fast-tracks psychedelic drug treatments for mental illness
cameoplus_political 路 2026-04-18 路 3 articles
Trump signs order to speed research of psychedelics, including ibogaine
cameoplus_political 路 2026-04-18 路 3 articles
Trump signs order to speed up psychedelic drug reviews with Joe Rogan
cameoplus_political 路 2026-04-19 路 2 articles
Trump signs order to fast-track FDA review of psychedelics for mental health
cameoplus_political 路 2026-04-19 路 2 articles
Trump signs order to speed psychedelic drug reviews, including ibogaine
cameoplus_political 路 2026-04-18 路 2 articles
Trump eases rules, expands access to psychedelics like LSD in the U.S.
cameoplus_political 路 2026-04-18 路 2 articles
Trump signs order to speed FDA review of psychedelics, including ibogaine
cameoplus_political 路 2026-04-18 路 2 articles
Trump signs order to speed review of psychedelic drugs including ibogaine
cameoplus_health 路 2026-04-19 路 1 articles
Executive order expands psychedelic therapy for veterans with PTSD
cameoplus_health 路 2026-04-19 路 1 articles
Trump accelerates investigation into psychedelic treatments and asks if he can take them
cameoplus_health 路 2026-04-19 路 1 articles
FDA to speed review of psychedelic medicines